N/A N=66 Comparison of the Effectiveness of USG and Palpation Guidance Steroid Injection in Patients With Plantar Fasciitis
Plantar Fasciitis
Primary: Pain Severity — 8.50; 8.31 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=84 Plantar Heel Pain: Multisegment Foot Motion and Muscle Function, FFI Translation, and Evaluation of Treatments
Plantar Fasciitis
Primary: Worst Pain — 5.96; 5.74; 3.91; 4.08 score — p=0.660
N/A N=114 Photobiomodulation for Plantar Fasciitis
Plantar Fascitis
Primary: Foot and Ankle Ability Measure (FAAM) — 66.2; 72.4; 69.9; 69.3 percentage of total score
Phase 2 N=176 Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis
Plantar Fibromatosis
Primary: Change From Baseline to Day 57 in the Foot Function Index (FFI) Pain Subscale Score — -9.844; -8.417 score on a scale — p=0.274
Phase 2 N=17 Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
Desmoid Tumors · Aggressive Fibromatosis
Primary: Number of Participants With a Complete Response (CR) + Partial Response (PR) — 0; 5; 1; 11 Participants
N/A N=17 Botulinum Toxin Effects on Plantar Ulcer Recurrence
Diabetes Mellitus · Peripheral Neuropathy · Plantar Ulcers
Primary: Plantar Flexor Muscle Strength — -8; 3; 6 Plantar Flexor Torque (Nm)
N/A N=60 Mechanisms of Manual Therapies in CAI Patients
Ankle Inversion Sprain · Chronic Instability of Joint
Primary: ML COP Velocity From Baseline to Post Intervention — 119.91; 118.91; 121.07; 116.99 % modulation — p=0.824
N/A N=69 Low-Level Laser Therapy for Plantar Fasciitis
Plantar Fascitis
Primary: Foot and Ankle Ability Measure (FAAM) — 47.00; 45.28; 11.65; 11.72 Percentage of function
N/A N=65 Validation of Plantar Orthoses for Abnormal Plantar Arch Using a New Non-invasive Clinical Imaging System
Flat Feet · High Arched Foot
Primary: Change From Baseline in Body's Postural Symmetry Index(SSIM Gray) at 2 Months — -0.031; 0.010 score on a scale
Phase 3 N=87 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Desmoid Fibromatosis
Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001
Phase 3 N=142 Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Desmoid Tumor · Aggressive Fibromatosis
Primary: Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause. — NA; 15.1 Months — p=< 0.001
Phase 2 N=9 A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Desmoid Tumor
Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63
Phase 2 N=16 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study
Diabetic Foot Ulcer · Offloading
Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion
Phase 1 N=41 Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis
Chronic Plantar Fasciitis
Primary: Visual Analog Scale Score - General Heel Tenderness — 46.7; 47.5 score on a scale
N/A N=30 Efficacy of Dry Needling in Plantar Fasciitis
Fasciitis, Plantar
Primary: Ultrasonographic Evaluation of the Thickness of the Affected Plantar Fascia, in Longitudinal View. — 5.3; 4.7 millimeters